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ABSTRACT
The rhodium (II) complexes Rh2(tfa)4.2(tfac) and Rh2(tfacam)4 (tfacam CF3CONH-,tfa CF3COO-,
tfac CF3CONH2) were synthesized and characterized b) microanalysis and electronic and vibrational
spectroscopies. Rhz(tfacam)4 was tested both in vitro (U937 and K562 human leukemia cells and Ehrlich
ascitic tumor cells) and in vivo for cytostatic activity and lethal dose determination, respectively. This is the
first rhodium tetra-amidate to have its biological activity evaluated. The LDs0 value for Rh2(tfacam)4 is of the
same order as that of cisplatin, and it was verified that the rhodium complex usually needs lower doses than
cisplatin to promote the same inhibitory effects.
INTRODUCTION
In 1969, Rosenberg and coworkers studied the effect of electric fields on the growth ofEscherichia coli
and noted that platinum compounds of cis configuration showed cytostatic activity [1]. Today, platinic
derivatives are widely used in tumor therapy, specially against testicular or ovarian carcinomas, and bladder,
head and neck tumors [2]. The biological activity of cisplatin and other platinum derivatives has already
been the scope ofnumerous reviews [3].
Figure Figure 2
Following the pioneering work of Rosenberg, complexes of transition metals other than platinum
such as titanium, ruthenium [2], iridium [4] and rhodium have been and are still being tested for antitumor
activity. The rhodium carboxylates, whose dimeric structure is shown in Figure (R bridging ligand
substituent group; L axial coordinating ligand which may be absent), are particularly noteworthy among
the rhodium compounds.
The antitumor activity of rhodium complexes was first reported by Bear and coworkers [5]. Rhodium
butyrate (R C3H7 in Figure 1) showed high in vitro cytostatic potential and in vivo antitumoral activity
but with toxicity higher than that of cisplatin [2,6,7]. For this reason, this class of dinuclear complexes
remains under study, and it is expected that structures may be found that ideally would have maximum
antineoplasic effect with minimum or no toxic effect. Several dinuclear rhodium (II) complexes have been
synthesized with this objective [8].
The hopes regarding the chemotherapeutic potential of rhodium amidates (Figure 2) are based on the
pioneering work described by Bear [9] and on previous findings for platinum and other metal compounds
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[3a, 10] which show that one of the main factors determining biological activity is the presence of at least one
free NH group in the molecule in order to establish hydrogen bonds with nucleotide phosphate groups.
A number of rhodium tetra-amidates have been synthesized and characterized 11 and in this work we
report some chemical properties and the pharmacological parameters ICs0 and LDs0 of the complex,
Rh2(tfacam)4 (Figure 2; R CF3); L can be a water molecule. To our knowledge, this is the first time that a
rhodium tetra-amidate has had its biological activities reported [12].
MATERIALS AND METHODS
Reagents: RhCl3.xH20 was purchased from Fluka. Chloroform and trifluoroacetamide (tfac) were from
Aldrich Chemicals. A commercial solution of cisplatin (Platinil 10) was from Quiral Quimica do Brasil S/A
and TweenVM-80 was from Baker. Using previously described methods, we obtained rhodium acetate,
Rhz(ac)4 [13]. Rhodium trifluoroacetate (R CF3 and L is absent in Figure 1) was obtained in yields of-
60% through dropwise addition of ethanolic solutions of RhCI3 over NaOOCCF3, a slight modification of a
method described earlier [8c].
Melting reaction" The synthesis of the complex Rh2(CF3CONH)4 was adapted from the literature
[1 a,b]. The starting reagents Rh2(ac)4 and tfac were previously treated in order to achieve the desired
reaction course. The amide (- 2 g; 17.7 mmol) was dried under vacuum for 30 minutes, at temperatures
between 20 and 40oC, to eliminate any trace of water or trifluoroacetic acid. 200 mg (0.45 retool) of Rhz(ac)4
were heated to 100oC for 30 minutes in a stoppered 50 mL round flask with a magnetic stirrer bar. This
system was immersed in a 144 to 148oC silicon oil bath for 2 hours. The flask was sealed with TeflonTM
tape after inner pressure compensation, which occurred after some seconds.
After cooling, the crystals were sublimed during 10 hours in an Abderhalden equipment heated to
56oC with acetone. An amorphous and hygroscopic purple solid was obtained whose elemental analysis was
consistent with the stoichiometry Rhz(CF3CONH)4(CF3CONH2)2 (Calculated" C 16.38%; H 0.59%; N
9.55%; Experimental: C 16.12%;H 1.59%; N 9.27%).
Rh2(tfa)4.2(tfac) (L CF3CONH2 in Figure 1)" The adduct between Rhz(tfa)4 and tfac was prepared
by refluxing the reagents in chloroform for 10 minutes, followed by slow solvent evaporation in air.
(Calculated: C 16.31%; H 0.46%; N 3.17%; Experimental: C 16.23%; H 0.63%; N 2.91%).
Electronic Spectroscopy: The electronic spectra in the range of 190 to 700 nm were registered with a
Hitachi U-3000 Spectrophotometer, with cm quartz cells using W and D2 lamps. The aqueous solutions
were 10-3 and 10-4M for visible and ultraviolet (UV) spectrometry, respectively.
Vibrational Spectroscopy: The infrared spectra in the range of 500 to 4000 cm-1 were obtained with a
Perkin-Elmer FT-IR equipment, in KBr pellets. The Raman spectra of the rhodium complexes were obtained
in a Renishaw Ramascope equipment, with Ar+ (488 nm; Rhz(tfa)4.2(tfac)) or He/Ne (633 rim;
Rhz(tfacam)4.2(tfac))laserexcitation.
In vitro Biological Assays: Cisplatin lx10-3 M and Rh2(tfacam)4 0.8 M aqueous solutions were
prepared. U937 and K562 human leukemia cells were cultivated in RPMI-1640 medium and kept in tissue
culture flasks at 37oC. Ehrlich ascitic cells were kept in Balb-c mice, sacrificed at the time of experiment, and
from which mL of intraperitonial liquid was extracted.
Inside a laminar flow cabinet, these cells were transferred to centrifuge tubes that were sealed and
centrifuged at 1400 rpm for 5 minutes. The cell pellet was resuspended in a mixture of culture medium and
PBS buffer solution. Cell counting was performed in Neubauer plates, working typically in the range of 3 to
4 x 105 cells/mL.
In the wells of tissue culture plates mL of cell solution, variable volumes of drug solutions and
sufficient saline to equalize the dilutions were then added. The culture plates were incubated for 24 hours at
37oC with 5% CO2 atmosphere. Control cells received only saline.
After 24 hours, the content of each well was pipetted to Eppendorf flasks and centrifuged at 1500 rpm
for 3 minutes. The supernatants were discarded and the pellet was resuspended in 500 mL of PBS and 500
mL of Trypan blue solution. A small volume of each flask was transferred to Neubauer plates and the living
and dead cells were counted.
In vivo Biological Assays: After preliminary tests, a 2.5xl 0-3 M aqueous solution of Rh2(tfacam)4
containing 5% w/w ofTweenX-80 was prepared, in order to achieve adequate solubilization of the inorganic
compound. This solution was prepared by dissolving 0.071 g (0.079 mmol) of Rhz(tfacam)4.2(tfac) in the
minimum possible amount of an acetone-ethanol mixture (- 10:1) in a 25 mL flask, forming a deep red
solution characteristic of axial coordination with acetone. Then 1.25 g of TweenTM-80 was added, followed
by manual homogeneization and elimination of the organic solvents through N2 bubbling for to 1.5 hours.
After evaporation, distilled water was carefully added to complete 25 mL. This final solution was purple.
Volumes of this solution ranging from 0.2 to 0.5 mL were injected intraperitoneally in groups of 10
to 11 male Balb-c mice (average weight: 22.5 g). The dead animals were counted after 6 days.
RESULTS AND DISCUSSION
Melting Reactiotr The yield of the reaction between Rh2(ac)4 and tfac was quantitative and the
described method is reproducible. Drying of the amide proved to be important since traces of trifluoroacetic
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acid, the tfac hydrolysis product, could be involved in reduction processes of Rh(II) to RhO, a phenomenon
observed during our early tests.
Rhz(tfacam)4 is insoluble in chloroform, soluble in acetone, methanol and ethanol and moderately
soluble in water. Under prolonged heating its solubility decreases significantly, a behavior similar to some
Rh binuclear compounds such as citrate and other alkanoates [14]. In such situations, the molecules probably
undergo polymerization, in which some of the oxygen atoms of the bridging ligands coordinate at the axial
position of a neighboring molecule forming chains.
Methanol solutions of Rhz(tfacam)4.2(tfac) were prepared and mixed with an excess of several ligands
that could, in principle, displace the tfac molecules and occupy the axial positions. The aim in this case was
a qualitative verification of the chemical properties of this complex. Table reports the results. These data
show that the axial positions are passive to ligand exchange, giving rise to new adducts with color patterns
different from that of Rh carboxylates. These usually show blue or green adducts for coordination through O,
pink or red for coordination through N and orange through S or P. In the case of Rh2(tfacam)4, adducts
coordinated axially through O are reddish or purple and are yellow for coordination with pyridine, DMSO or
R3P, reflecting changes in the energy levels ofthe molecular orbitals of the compounds a,e].
In crystals, it was observed [lib] that the ,F
_O.--Rh
Rh2(tfacam)4 complex can display hydrogen bonds 17" !h
"’C between the amide H atom and one of the F atoms of the
CF3 group, which would be approximately in the NCO F N---
plane (Figure 3). Whether or not this interaction is more ",%0, H/ important than that ofNH groups with proteic substrates Figure 3
in biologic environments is an issue for future research.
For the tetra-amidates there are four possible geometric isomers, according to the position of the NH
groups. Generally, the isomer with Rh-N bonds in cis, as in Figure 2, is preferentialy obtained (- 94%
[1 b,c]), a fact that led Bear and coworkers to suggest the restriction that "the nitrogen of the entering
amidate ion cannot bind trans to any other nitrogen on the same rhodium atom" 11 d].
Electronic Spectroscopy: Table II summarizes the visible and UV spectral data in aqueous solutions.
The electronic transitions ofrhodium carboxylates have already been the scope of a number of reports 15a-c],
with the assignements shown in Table II being widely accepted.
The electronic spectra of rhodium carboxylates and tetra-amidates (as Rh2(CH3CONH)4 and
Rh2(CF3CONH)4 are qualitatively similar [15d], although rhodium amidates possess a band at 350 400
nm which sometimes cannot be observed, due to an overlap with UV absorption, and was tentatively
assigned to a *Rh-ah to tJ*Rh-O or tJ*Rh-N transition [1 lb].
Table I: Effect ?f ligand addition to Rh2(tfacam)4..2(tfac)
Ligand 91"/nm
Pyridine 472
Dimethylsulfoxide(DMSO) 482
Imidazole 480 (shoulder)
Acetonitrile 508
Dimeth lformamide 540
* )l is a typical absorption band of the Rh dimeric compounds (-500-600
nm). Its position is altered by axial substitution and defines the apparent
color ofthe adducts.
Table II" ) (nm) and E (M-lcm-1) for some rhodium complexes in water solution
ComPlex ,1 El ’2 E2 )3 E3 4 E4
Rh2(tfa)4 581 169 442 115 255(s) -4400 226 13000
Rh2(tfacam)4 552 43.9 -250(s) 218(s) -7000
,1"/1;*Rh-Rh---(Y*Rh-Rh; ,2 I1;*Rh-Rh(Y*Rh-O; 3 (shoulder): (YRh_Rh_..)Y*Rh.Rh;)4" (YRh-O--)O’*Rh-Rh
(s) shoulder --: not observed
Vibrational Spectroscopy: In KBr pellets, primary amides have several characteristic infrared (IR)
frequencies: (NH as at 3330 and at 3180 cm-l; a band at 1650 cm-1 corresponding to (co (Amide I
band); a iNH (Aide II band) at 5Hl’ 1650 cm-I and weak one at 1400 cm-1 from (cy. Amide and
Amide II bands may sometimes overlap. (CF usually falls in the 1000-1400 cm-1 range [16]. Table III
summarizes the relevant IR data for the free ligand tfac and some rhodium complexes. Table IV lists the
main bands observed in the 100 to 500 cm-1 range. The Rh-Rh bond stretching frequency is practically
independent of substitutions in the bridge ligands, but depends strongly on the nature and influence of the
axial ligands. Its assignment has already been the subject of some controversy [cfr 17-21]. Using normal
coordinate analysis, Pruchnik and coworkers [17] concluded that both of the reported bands (in the 170
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180 and in the- 280 300 cm-1 region) show a component of the Rh-Rh vibration, not as pure bands but
instead coupled with Rh-Obridge vibrations, for example.
Table III: Main IR bands for the complexes (cm-), in KBr pellets
Compound Bands/,cm- tfac(freeligand) 3370 (s)
3192 (s)
1644 (broad)
1458 (m)
1153 (s)
Rh2(tfa)4 1668 (s)
46 (w)
1194 (s)
Rhz(tfacam)4.2(tfac), see Figure 6 3330 (broad)
1659 (s)
1431 (m)
1178(s)
Rhz(tfa)4.Z(tfac) 346(s)
1663(s)
1459(m)
1192(s)
1. VCO,carbox CO stretching from rhodium arboxylate
s strong; m medium; w weak
Proposed assignment
VNH,as
VNH,s
overlap Amide I/Amide II
vCN
VCF
VCO,as
VCO,s
VCF
VNH (overlap as/s)
overlap AmideI/Amide II
VCN
VCF
VNH (overlap as)s)
(Am.I/Am.II) or Vco,carbox ?
vco,s or VCN .9
VCF
With amidates as bridging ligands, the Rh-Rh bond will be subject to a different environment.
Rh2(CH3CONH)4 or Rhz(CF3CONH)4 have Rh-Rh distances about 0.4 nm greater and VRh-Rh around 15
cm-1 [23]’smaller than Rh2(ac)4. These effects could be explained either by steric reasons (the amidate O-C-N
angles are slightly bigger than the O-C-O angle of the carboxylates) or by electronic reasons (amidates are
better n-acceptors than carboxylates, and so they can remove electron density from the Rh-Rh bond) 15,22].
A tentative assignment of the Rh-Rh vibration was carried out for the compounds Rhz(tfa)4.2(tfac) and
Rhz(tfacam)4.2(tfac). The VRh-Rh value for Rhz(tfa)4 was reported as being 332 cm- [8h]. Axial coordination
inserts electrons in antibonding levels of the Rh-Rh bonding molecular orbitals, so we would expect a slight
weakening of this bonding and a consequent decrease of the VRh-Rh value when comparing Rh2(tfa)4 with
Rhz(tfa)4.2(tfac). This is indeed observed if we consider the predominant Rh-Rh vibrational band as being
that at 327 cm-I in Table IV. There is also a trend towards weakening the Rh-Rh bond if one compares
Rhz(tfa)4.2(tfac) with Rhz(tfacam)4.2(tfac). This is in fact observed ifwe consider the band at 313 cm-I in the
Raman spectrum for the complex Rhz(tfacam)4.2(tfac) (Table IV) to be mainly Rh-Rh in character.
Table IV: Main Raman bands for the complexes
Complex Absorption/em-1
Rhz(tfa)4.Z(tfac) 157 (s); 192 (m); 282 (w); 327 (m); 464 (w); 541 (w’)
Rhz(tfacam)4.2(tfac) 173 (w); 179 (w); 313 (s); 432 (w); 502 (w); 524 (m)
In vitro Biological Assays: After counting the live and dead cells of the different lines exposed to the
two tested drugs, we built the suitable dose-response curves using probit transformation, a statistical
treatment that changes values of a normal curve into a straight line. The ICs0 parameter was determined from
all these curves and the final values are presented in Table V. Both in this case and in the LDs0
determinations, all values reported were calculated under the assumption that the axial L positions were
occupied with water molecules after solubilization of Rhz(tfacam)4.
Table V: Average ICs0 (xl0-SM) values of the assayed drugs
Tumor Rh2(tfacam)4 Cisplatin
lineage
U937 4.8 13.0
K562 7.8 7.9
Ehrlich 3.0 6.4
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Dose (mL)
0.2
0.3
0.4
0.5
Table VI: LD50 values
Live/Dead Total of
animals
8/2 10
10/1 11
8/3 11
1/9 10
Conc.’ (mol/kg)
2.2 x 10-5
3.4 x 10-5
4.5 x 10-5
5.6 x 10-5
Analysing the comparative data of IC50 we see that the rhodium drug usually requires half of the
molar dose of cisplatin to achieve the same inhibitory effect. Nevertheless, with respect to K562 cells, both
act in the same concentration ranges.
In vivo Biological Assays: Table VI shows the results of LD50 determinations employing male Balb-
c mice.
We obtained LDso of the rhodium complex as being 4.8 x 10-5 mol/kg (fidutial limits: 6.1 x 10-5
and 3.7 x 10-5 mol/kg). LDro, the lethal dose for 10% of the population, is a good first approach for tumor
therapy tests. For Rh2(tfacam)4, its value is 2.4 x 10-5 mol/kg (fidutial limits: 3.7 x 10-5 and 1.5 x 10-5
mol/kg). In their review, Hydes and Russell [23a] reported the LD50 of intraperitoneally administered
cisplatin in Swiss white female mice [23b] as being 4.33 x 10-5 mol/kg. Assuming that this value can be
compared with our results, we see that Rh2(tfacam)4 has the same order of toxicity as cisplatin.
CONCLUDING REMARKS
These findings encourage us to continue research with the Rh2(tfacam)4 complex. Presentely, we are
undertaking survival rate determinations and anatomopathological experiments in Balb-c mice, in order to
explore the potential of our compounds in cancer treatment. Another line of research will involve the
interaction of this complex with selected proteins.
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